Grape Seed Extract Shows Potential to Slow Prostate Cancer Progression
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxA New Potential Treatment For Early Prostate Cancer: TGW101
/0 Comments/in Clinical Trial, Non-Metastatic, Not PCa related, Phase 1/by MaxPhase 2 Trial Recruiting: WOMBAT Study on Bipolar Androgen Therapy for Prostate Cancer
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxPhase 1 Enrolling: Novel Copper-61 Radiotracer Shows Promise in Prostate Cancer Precision Imaging
/0 Comments/in Clinical Trial, Localized, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxPhase 2: Food as Medicine Research from City Of Hope
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxPhase 1 Trial of STX-478 Shows Promise for PI3K-Mutated Solid Tumors with Reduced Toxicity
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data talazoparib theranostics
Latest Posts
- Positive Results From Phase 3 Trial of CAN-2409 for Localized Prostate Cancer Led to RMAT Designation May 29, 2025
- UPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC May 29, 2025
- Phase 2 Clinical Trial: JSB462 (Luxdegalutamide) in Combination With Abiraterone for mHSPC May 29, 2025
- Phase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) May 29, 2025